Evaluation of Efficacy and Safety of Long-Acting Risperidone Microspheres in Patients With Schizophrenia or Schizoaffective Disorders, Who is Receiving Psychiatric Home-Care Treatment, When Switching From Typical Depot or Oral Antipsychotics to Long-Acting Risperidone Microspheres.
Phase of Trial: Phase IV
Latest Information Update: 16 Dec 2013
At a glance
- Drugs Risperidone (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Therapeutic Use
- Sponsors Johnson & Johnson
- 06 May 2009 Actual patient number (27) added as reported by ClinicalTrials.gov.
- 06 May 2009 Actual initiation date (May 2007) added as reported by ClinicalTrials.gov.
- 06 May 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.